We are interested in studying diabetic vasculopathies. Patients with type 2 diabetes mellitus or metabolic syndrome have aggressive forms of vascular disease, possessing a greater likelihood of end-organ ischemia, as well as increased morbidity and mortality following vascular interventions. Our long term research aims to change the way we treat arterial disease in diabetes by:
- Understanding why arterial disease is more aggressive in diabetic patients, with a focus in redox signaling in the vasculature.
- Developing targeted systems using nanotechnology to locally deliver therapeutics to the diseased arteries.